Forum Hiv
Vuoi reagire a questo messaggio? Crea un account in pochi click o accedi per continuare.

Terapie del Futuro

Andare in basso

Terapie del Futuro Empty Terapie del Futuro

Messaggio Da Gex Mer 16 Feb - 7:55

Interessante articolo su quello che cambiera' nell'approccio farmacologio alle terapie dei prossimi anni.
In breve le terapie convenzionali saranno sempre piu sostituite da terapie mirate come anticorpi monoclonali, terapie geniche e terapie a cellule staminali, sopratutto per i minori effetti collaterali, anche se, al momento queste terapie innovative non portano alla guarigione definitiva.

[Devi essere iscritto e connesso per vedere questo link]

Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the MarketFailure of Conventional Therapies in Curing Chronic Diseases has Created High-unmet Needs





FOR IMMEDIATE RELEASE
PRLog (Press Release) – Feb 16, 2011 – Conventional therapies such as chemotherapy and hormone therapy, although controlling progression of diseases, are often associated with potential side-effects. For example side-effects due to chemotherapy in cancer range from nausea and hair loss to thrombocytopenia and neutropenia. Patients often succumb to death due to the side-effects and not the cancer. Chemotherapies do not possess the selective target characteristics. Once administered, they induce systemic action throughout the body leading to these potential side effects.

For Sample Pages, please click or add the below link to your browser:
[Devi essere iscritto e connesso per vedere questo link] ...

Targeted therapies such as monoclonal antibodies have thus far shown better efficacy and safety profiles compared to chemotherapies. However, they too do not induce complete remission of the disease. They either reduce signs and symptoms of the disease or slow down the growth of tumors. The inability of these therapies to cure diseases has created significant unmet needs in cancer, hepatitis, HIV and autoimmune diseases.

Many marketed monoclonal antibodies such as Avastin, Rituxan, and Remicade are being approved for multiple indications resulting in increased potential patient pool for these products. Alemtuzumab, which is approved for b-cell chronic lymphocytic leukemia, is in phase III clinical trials for multiple sclerosis. Remicade is approved to treat plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, adult Crohn's Disease, pediatric Crohn's disease, ulcerative colitis, and ankylosing spondylitis. Remicade is also in Phase III clinical trials for the treatment of juvenile rheumatoid arthritis and in Phase II clinical trials for the treatment of sarcoidosis, chronic obstructive pulmonary disease (COPD), cachexia, and asthma. Enbrel, has been approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis

GBI Research, the leading business intelligence provider, has released its latest research, “Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market.” It provides key data, information and analysis on the main types of targeted therapeutics and their key pipeline molecules. The report provides complete profile of key promising therapies in the pipeline. The report provides comprehensive analysis of key M&A and Licensing deals of key companies and analyses the outcome of the respective deal. It also analyses the regulatory scenario with main focus on gene therapy and stem cell therapy.

Key biotech and pharmaceutical companies are profiled along with their latest deals involving targeted therapeutics.

It is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts

For further details, please click or add the below link to your browser:
[Devi essere iscritto e connesso per vedere questo link] ...
.
Visit our report store: [Devi essere iscritto e connesso per vedere questo link]

For more details contact:
[Devi essere iscritto e connesso per vedere questo link]
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

# # #

GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

--- end ---
Gex
Gex
Admin

Messaggi : 2565
Data d'iscrizione : 20.12.10

Torna in alto Andare in basso

Torna in alto


 
Permessi in questa sezione del forum:
Non puoi rispondere agli argomenti in questo forum.